Precise Insights

Advanced Data and AI for Bladder Cancer

On-demand access to the largest and most sophisticated oncology data for accelerated RWE and improved patient outcomes.

Advanced Data and AI for Bladder Cancer

See some of the 1000s of data elements we offer:

Structured Fields

Request a Demo

 

Structured Fields

labs

Results from variety of patient tests

Visits

Oncology practice visits

Observations

Tumor-related observations plus vitals, biometrics, pain, and more

Procedures

Surgeries, radiation, biopsies, imaging, chemotherapy, etc.

Medications

Start and end dates, brand vs. generic codes, dosage, duration, and cycles

Diagnoses

Disease state, status, severity, and metastasis

Expert Abstraction

Request a Demo

 

Expert Abstraction

full ngs panel

Complete genomic report with treatment exposure and clinical outcomes

Disease Progression

Directly-observed measures of critical endpoints

Adverse Events

Different types of adverse responses

Histology

Classification into multiple categories

Enriched Data

Request a Demo

 

Enriched Data

Cost & Utilization

Adjudicated costs with linked claims data

Safety, Comorbidities

Pre-cancer and claims charge events

Specialty Pharmacy & Hub

Rx acquisition status details

Payer & Formulary

Drug tiers and coverage

Social Determinants

Social and physical environment factors

AI & Model-Based Insights

Request a Demo

 

AI & Model-Based Insights

Cancer Subtype

Cancer type when ICD code is unknown

ECOG

Predict oft-missing performance score

Metastatic Status

Impute missing data from unstructured notes

Date of Initial Dx

Impute index event

EGFR Status

Impute specific gene mutation

Line of Therapy

Regimen or progression-based drug classes

Patient Adherence

Identify root cause of product switching

Patient Acquisition

Predict factors driving patients’ brand decision

Request Data Count

Explore ConcertAI datasets to see how many patients are in your disease area and meet study criteria.

bladder cancer

Research Studies

Our scientists regularly publish leading RWE studies in the fields of clinical development and health economics and outcomes research.

bladder research study

Treatment Patterns and Outcomes in Stage IV Bladder Cancer

Current real-world data regarding treatment patterns in advanced bladder cancer are limited. This study describes patient characteristics, treatment patterns, and effectiveness outcomes for stage IV bladder cancer.

See Full Study
Methods

Retrospective observational study

Analysis
  • Patient characteristics, treatment patterns, efficacy outcomes​
  • Progression-free survival​
  • Overall survival​
Patient Criteria
  • Adults with Stage IV bladder cancer
  • Diagnosed between 1/2008 and 6/2015
Results

508

Eligible patients

Findings:

Of patients received first-line platinum-based chemotherapy

56%

Of patients received first-line platinum-based chemotherapy

Median months overall survival from start of Line 1 therapy

8.4

Median months overall survival from start of Line 1 therapy

Conclusion

This study highlights an unmet need in this population, particularly in a relapsed/refractory setting, and the need for improvement in outcomes.

Research for Clinical Genitourinary Cancer, 2018